EP0190464A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Novel anti-cancer drugs
Assignee: Yeda Research and Development Co Ltd
•
Filing: 1985-12-31
•
Granted: —
•
Expires: 2005-12-31
Abstract
Abstract Described are complexes between a physiologically acceptable macromolecular carrier and an anti-tumor active platinum compound useful as anti-cancer drugs.
Inventors
- 👤 Ruth Arnon
- 👤 Meir Wilchek
- 👤 Bilha Schechter
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-26 17:02
CPC Classifications
A; A61; A61K; A61K47/00; A61K47/50; A61K47/51; A61K47/56; A61K47/61; A61K33/00; A61K33/24; A61K33/243; A61K47/62; A61K47/64; A61K47/645; A61P; A61P35/00
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
12 words
A complex between a physiologically acceptable macromolecular carrier and a platinum compound.
Claim 2
Dependent Claim
12 words
A complex between a physiologically acceptable macromolecular carrier and a platinum compound.
Claim 3
Dependent Claim
21 words
A complex according to claim 1, wherein the platinum compound is K 2 PtCl 4 , cis-Pt or cis aq .
Claim 4
Dependent Claim
34 words
A complex according to claim 1 or 2, wherein the carrier is a polysaccharide or a polyamino acid, optimally substituted by a functional qroup facilitating the formation of the complex with the platinum compound.
Claim 5
Dependent Claim
15 words
A complex according to claim 3, where the substituents are amino, carhoxy or hydroxy groups.
Claim 6
Dependent Claim
32 words
A complex according to any of claims 1 to 4, wherein the carrier is a oolysaccaride selected from dextran, sepharose, agar-agar and functional derivatives of any of these and from polyamino acids.
Claim 7
Dependent Claim
22 words
A complex according to any of claims 1 to 5, wherein the carrier is dextran-amine, carhoxymethyl dextran, polu-L-glutamic acid or poly-L-aspartic acid.
Claim 8
Dependent Claim
19 words
Complexes between polymeric carriers and platinum compounds substantially as hereinbefore described and with reference to any of the Examples.
Claim 9
Dependent Claim
19 words
Complexes between polymeric carriers and platinum compounds substantially as hereinbefore described and with reference to any of the Examples.
Claim 10
Dependent Claim
31 words
A pharmaceutical composition comprising as active ingredient a therapuetically active Quantity of a macromolecular carrier-platinum complex as claimed in any of claims 1 to 7, with a suitable carrier or adjuvant.
Claim 11
Dependent Claim
28 words
A pharmaceutical composition as claimed in claim 8, wherein the active ingredient is a complex of cis-Pt with dextran-amine with carboxymethyl-dextran, with poly-L-glutamic acid or with poly-L-aspartic acid.
Claim 12
Dependent Claim
32 words
A pharamceutical composition according to claim 8, wherein the active ingredient is a complex of cis-aq with a physiologically acceptable polymeric carrier selected from dextran-amine, carboxymethyl dextran, poly-L-glutamic acid and poly-L-glutamic acid.
Claim 13
Dependent Claim
16 words
A pharmaceutical composition as claimed in any of claims 7 to 10 in unit dosage form.
Claim 14
Dependent Claim
30 words
A pharmaceutical composition containing as active ingredient a conjugate or complex of a macromolecular carrier and a Pt-complex substantially as hereinbefore described and with reference to any of the Examples.
Claim 15
Dependent Claim
30 words
A pharmaceutical composition containing as active ingredient a conjugate or complex of a macromolecular carrier and a Pt-complex substantially as hereinbefore described and with reference to any of the Examples.
Claim 16
Independent Claim
27 words
A method for the treatment of tumors which comprises administering to the patient an effective Quantity of a composition claimed in any of claims 8 to 12.
Claim 17
Dependent Claim
17 words
An anti-cancer drug suitable for covalent linkage to anti-tumor antibodies for the purpose of immunotaroeting or immunoimaging.
Claim 18
Dependent Claim
17 words
An anti-cancer drug suitable for covalent linkage to anti-tumor antibodies for the purpose of immunotaroeting or immunoimaging.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.